TCM
TEVA icon

Tekla Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Tekla Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-68,600
Closed -$3.69M – 111
2014
Q3 		$3.69M Buy
+68,600
New +$3.63M 0.17% 95

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tekla Capital Management's TEVA Position: Q2 2023 in Review

Tekla Capital Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2023 at 459,651 shares worth $3.46M. The position accounts for 0.14% of the portfolio, ranked #95.

Tekla Capital Management first reported a position in TEVA in Q2 2013 and has held it in 41 quarters since. The position peaked at $87.6M in Q4 2015. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Tekla Capital Management held 459,651 shares of Teva Pharmaceuticals worth $3.46M as of Q2 2023.
  • Tekla Capital Management left its Teva Pharmaceuticals share count unchanged in Q2 2023.
  • Teva Pharmaceuticals made up 0.14% of Tekla Capital Management's portfolio in Q2 2023, its #95 holding.
  • Tekla Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
  • Tekla Capital Management's Teva Pharmaceuticals position peaked at $87.6M in Q4 2015.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.